Clinical Trial Update: Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating BioTTT001 for recurrent high-grade glioma, currently enrolling by invitation to assess safety and preliminary efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma

Drugs mentioned

• BioTTT001

Snippet

Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Conditions: Recurrent High-grade Glioma | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION